Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for myeloproliferative neoplasms
DMRA•Corporate deck highlights mutCALR pipeline and market opportunity
Damora outlined a mutCALR-focused pipeline for myeloproliferative neoplasms, targeting essential thrombocythemia and myelofibrosis.
- Lead antibody DMR-001 entered Phase 1/1b CLARITY-101, with two proof-of-concept readouts expected beginning mid-2027.
- Damora reported about $541 million in cash to fund DMR-001 through proof-of-concept and into registrational development.
- DMR-002, an Fc-enhanced anti-mutCALR antibody, is slated for a first regulatory submission in 2H 2026; DMR-003 is targeted in 2027.
- The deck pegged the US mutCALR-driven MPN opportunity at more than $5 billion, citing roughly 42,000 prevalent patients across ET and MF.
